Logo-bi
Bioimpacts. 2019;9(1): 1-3. doi: 10.15171/bi.2019.01
PMID: 30788254        PMCID: PMC6378097

Editorial

Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities

Nastran Hashemzadeh 1,2, Khosro Adibkia 1,3 ORCID, Jaleh Barar 1,3 * ORCID

Cited by CrossRef: 5


1- Martynchyk A, Chowdhury R, Hawkes E, Keane C. Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma. Cancers. 2023;15(21):5217 [Crossref]
2- Li X, Ma Z, Wang H, Shi Q, Xie Z, Yu J. Research progress of copper-based metalā€“organic frameworks for cancer diagnosis and therapy. Coordination Chemistry Reviews. 2024;514:215943 [Crossref]
3- Zhou Y, Wang H, Luo Y, Tuo B, Liu X, Li T. Effect of metabolism on the immune microenvironment of breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(2):188861 [Crossref]
4- Shim N, Cho H, Jeon S, Kim K. Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy. J Pharm Investig. 2024;54(1):13 [Crossref]
5- Hashemzadeh N, Dolatkhah M, Aghanejad A, Barzegar-Jalali M, Omidi Y, Adibkia K, Barar J. FolateĀ Receptor-Mediated Delivery of 1-MDT-Loaded Mesoporous Silica Magnetic Nanoparticles to Target Breast Cancer Cells. Nanomedicine (Lond). 2021;16(24):2137 [Crossref]


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge